Csl Ltd ADR (CSLLY)

$29.79 +1.69 (6.01%)
Market Cap 53.83B
Revenue (ttm) 15.56B
Net Income (ttm) 3.00B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 15.16
Profit Margin 19.30%
Debt to Equity Ratio 0.54
Volume 216,100
Avg Vol 327,574
Day's Range N/A - N/A
Shares Out 1.92B
Stochastic %K 100%
Beta 0.57
Analysts Sell
Price Target $28.40

Company Profile

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with cond...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9389 1911
Fax: 61 3 9389 1434
Website: www.csl.com
Address:
655 Elizabeth Street, Melbourne, Australia
alpenland
alpenland Aug. 19 at 4:18 PM
$CSLLY target 50$ 😁
0 · Reply
alpenland
alpenland Aug. 18 at 4:22 PM
$CSLLY rebound in action😀👍🏼🚀
0 · Reply
prismmarketview
prismmarketview Nov. 20 at 4:24 PM
(OTCQX: $CSLLY) #CSLBehring is committing approximately $1.5 billion over the next five years to expand its U.S. plasma-derived therapy manufacturing, strengthening the American plasma supply chain, meeting rising demand for immunoglobulin treatments, and creating hundreds of high-quality jobs across its CSL Behring network. https://prismmarketview.com/csl-commits-1-5-billion-to-strengthen-u-s-plasma-supply-chain/
0 · Reply
inelegantinvest
inelegantinvest Oct. 31 at 1:14 AM
CSL’s vaccine spinoff plans just caught a cold. The Seqirus separation has been delayed indefinitely due to weak flu shot uptake and market conditions. Details: https://www.stockspinoffs.com/2025/10/30/csl-delays-seqirus-spinoff-amid-slumping-vaccine-demand/ $CSLLY
0 · Reply
inelegantinvest
inelegantinvest Oct. 23 at 2:09 PM
$CSLLY to spin out its vaccine arm, $ CSL Seqirus, by mid-2026 3,000 job cuts • USD 700-770 M charge • A$750 M buyback Will the spin unlock value — or invite execution risk? Details 👉 https://www.stockspinoffs.com/2025/10/23/csl-seqirus-spinoff/
0 · Reply
LewisDaKat
LewisDaKat Jun. 17 at 12:25 AM
News Article U.S. Food and Drug Administration Approves CSL's ANDEMBRY (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start https://marketwirenews.com/news-releases/u-s-food-and-drug-administration-approves-csl-s-ande-6800974205429602.html $CSLLY
0 · Reply
PenkeInvesting
PenkeInvesting Feb. 12 at 6:42 AM
I found you an Oversold RSI (Relative Strength Index) on the daily chart of CSL Ltd. Is that bullish or bearish? $CSLLY #RsiOversold #PINK
0 · Reply
George_Carlin_Lives
George_Carlin_Lives Feb. 11 at 7:25 AM
$CSLLY The market is punishing CSL for making money
0 · Reply
reg0sce
reg0sce Jan. 10 at 2:30 AM
$CSLLY $CSLLY Use to be a good company, but piss poor management has ran it in the ground. Unloading this turd!!
0 · Reply
Jeko44
Jeko44 Jan. 6 at 8:32 PM
$AKBA I don’t know if $CSLLY can afford us. Their market cap is only $85B…😉
0 · Reply
Latest News on CSLLY
No data available.
alpenland
alpenland Aug. 19 at 4:18 PM
$CSLLY target 50$ 😁
0 · Reply
alpenland
alpenland Aug. 18 at 4:22 PM
$CSLLY rebound in action😀👍🏼🚀
0 · Reply
prismmarketview
prismmarketview Nov. 20 at 4:24 PM
(OTCQX: $CSLLY) #CSLBehring is committing approximately $1.5 billion over the next five years to expand its U.S. plasma-derived therapy manufacturing, strengthening the American plasma supply chain, meeting rising demand for immunoglobulin treatments, and creating hundreds of high-quality jobs across its CSL Behring network. https://prismmarketview.com/csl-commits-1-5-billion-to-strengthen-u-s-plasma-supply-chain/
0 · Reply
inelegantinvest
inelegantinvest Oct. 31 at 1:14 AM
CSL’s vaccine spinoff plans just caught a cold. The Seqirus separation has been delayed indefinitely due to weak flu shot uptake and market conditions. Details: https://www.stockspinoffs.com/2025/10/30/csl-delays-seqirus-spinoff-amid-slumping-vaccine-demand/ $CSLLY
0 · Reply
inelegantinvest
inelegantinvest Oct. 23 at 2:09 PM
$CSLLY to spin out its vaccine arm, $ CSL Seqirus, by mid-2026 3,000 job cuts • USD 700-770 M charge • A$750 M buyback Will the spin unlock value — or invite execution risk? Details 👉 https://www.stockspinoffs.com/2025/10/23/csl-seqirus-spinoff/
0 · Reply
LewisDaKat
LewisDaKat Jun. 17 at 12:25 AM
News Article U.S. Food and Drug Administration Approves CSL's ANDEMBRY (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start https://marketwirenews.com/news-releases/u-s-food-and-drug-administration-approves-csl-s-ande-6800974205429602.html $CSLLY
0 · Reply
PenkeInvesting
PenkeInvesting Feb. 12 at 6:42 AM
I found you an Oversold RSI (Relative Strength Index) on the daily chart of CSL Ltd. Is that bullish or bearish? $CSLLY #RsiOversold #PINK
0 · Reply
George_Carlin_Lives
George_Carlin_Lives Feb. 11 at 7:25 AM
$CSLLY The market is punishing CSL for making money
0 · Reply
reg0sce
reg0sce Jan. 10 at 2:30 AM
$CSLLY $CSLLY Use to be a good company, but piss poor management has ran it in the ground. Unloading this turd!!
0 · Reply
Jeko44
Jeko44 Jan. 6 at 8:32 PM
$AKBA I don’t know if $CSLLY can afford us. Their market cap is only $85B…😉
0 · Reply
LewisDaKat
LewisDaKat Oct. 17 at 10:55 AM
$CSLLY $CSLLY Nhttps://marketwirenews.com/news-releases/csl-vifor-and-travere-therapeutics-announce-swissmed-8036968104308380.html ews out CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI (sparsentan) for the treatment of IgA Nephropathy
0 · Reply
swingingtech
swingingtech Oct. 17 at 7:04 AM
$TVTX $CSL $CSLLY https://wallstreetwaves.com/csl-vifor-and-travere-therapeutics-announce-swissmedic-approval-of-filspari-sparsentan-for-t
0 · Reply
reg0sce
reg0sce Aug. 18 at 6:27 PM
$CSLLY 5 years and still is the same spot, just a stall lame stock… Time to move on’
0 · Reply
Jeko44
Jeko44 Jul. 12 at 9:13 PM
$CSLLY another strong price gain and volume here today and the last 3 months.
0 · Reply
Jeko44
Jeko44 Jul. 11 at 1:57 PM
$AKBA $CSLLY is also up 3% today. They must be happy, too 🙂
0 · Reply
falconfly1
falconfly1 Jul. 7 at 10:43 PM
$HYPD $SHPH and $ANIP and $CSLLY and $GSK What is new and opportunity in $HYPD? 1 - Insider bought 1.5 million shares in July and paid 1 Million dollars 2 - Vanguard biggest institution in the world bought 5 million dollars for a call option 3 - First FDA MydCombi selling from April 2024, and they have a contract with Vision Source biggest Private Practice Optometrists in the USA and Canada. Vision Source multi a billion company. 4 - Second FDA's strongest eyedrop sales start the first of August and are expected to generate 15 to 40 million per quarter. 5 - 8 or 9 August earnings call, and it should be good. 6 - MicroPine and MicroLine are unmet need eyedrops for children and the result is coming in Q4 2024.
1 · Reply
Jeko44
Jeko44 Jul. 3 at 2:08 PM
$CSLLY the last time csl was this close to $100 was February…looks like it’s time for a break above
0 · Reply
Jeko44
Jeko44 Mar. 27 at 6:46 PM
$CSLLY still
0 · Reply
Jeko44
Jeko44 Mar. 3 at 10:51 PM
$CSLLY
0 · Reply
Financhill
Financhill Jan. 17 at 10:40 PM
$CSLLY is rated a Sell since January 16, 2024 and is 28% below its median level.
0 · Reply
Stock_Titan
Stock_Titan Jan. 3 at 1:00 PM
$CSLLY CSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe
0 · Reply